Hair Loss on GLP-1 Medication: What’s Causing It and How to Minimise It

Quick Answer

GLP-1 hair loss hit 3% to 6% of people on Wegovy or Zepbound in trials, against about 1% on placebo.

  • The likeliest cause is the weight loss, which can set off shedding months later.
  • Acute shedding stops within six months; test iron if it is heavy.
  • Scalp pick: Therapy-G’s 4 Step System Kit, a set routine with no prescription.
A wooden comb beside a bowl of leafy greens, representing nutrient support for GLP-1 hair loss.

If you’ve noticed more hair in the brush a few months into treatment, you’re not imagining it. GLP-1 hair loss is on the Wegovy and Zepbound labels, it is uncommon, and the weight loss looks more to blame than the drug. What you can work on is what you eat, what you get tested for, and what you put on your scalp while it passes.

Disclosure: This article contains affiliate links. If you purchase through these links I may earn a small commission at no extra cost to you.

What Is GLP-1 Hair Loss, and Why Does It Happen?

The most likely explanation is the weight loss. The authors of a 2026 study in The BMJ name weight loss and eating less as the likeliest mechanism, and the drug labels say the hair loss in their trials was associated with weight reduction. The shedding that fast weight loss sets off is called telogen effluvium: many growing hairs switch into their resting phase at once, then fall out together about three months later, anywhere from one to six months according to the StatPearls review of telogen effluvium.

Crash dieting and low protein intake are on the same review’s list of common triggers. A GLP-1 cuts how much you eat, so both are easy to fall into.

Shedding is not the only pattern people get. A 2025 scoping review in Cureus gathered nine studies, and only one of them typed the hair loss clinically: of 35 patients who lost hair, 19 had androgenetic alopecia, the inherited pattern thinning, against 10 with telogen effluvium, and 91.4% had lost hair before. Most of the nine had no dermatologist’s diagnosis behind them, and the authors say a causal link cannot be confirmed.

Whether the drug acts on the hair follicle directly is open. The Cureus authors float GLP-1 receptors on skin cells called dermal fibroblasts, an idea borrowed from skin-ageing research and not yet tested for hair. A 2026 review of 24 published studies in Science Progress found no human study showing a direct effect on follicles.

How Common Is Hair Loss on Wegovy and Zepbound?

In the trials behind the labels, a few people in every hundred reported hair loss on the drug, against about one in a hundred on placebo. The figures come from the Wegovy prescribing information and the Zepbound prescribing information, read in October 2026.

Medicine and dose Hair loss on the drug On placebo Women / men on the drug
Wegovy 2.4 mg (adults, 68 weeks) 3.3% 1% 4% / 0.9%
Wegovy 7.2 mg (adults, 72 weeks) 5.8% 1.0% 8.4% / 0.2%
Wegovy 2.4 mg (ages 12 and over) 4% 0% Not given
Zepbound 5 / 10 / 15 mg (adults, up to 72 weeks) 5% / 4% / 5% 1% 7.1% / 0.5%
Ozempic, Mounjaro, Rybelsus No rate given No rate given Listed only as reports after approval

Women reported it far more often than men on both drugs, by the labels’ own figures. The Science Progress review saw the same split and says it cannot tell whether that is biology or women noticing and reporting hair loss more.

Dose is a weaker signal than it is often made out to be. Zepbound’s rate stayed flat from 5 mg to 15 mg. Wegovy’s rose at 7.2 mg, the newer higher dose, where hair loss led to one permanent stop, one pause and five dose reductions, against none at 2.4 mg. You may read online that semaglutide above 2 mg brings more hair loss; in the Science Progress review behind that claim, the clearest example is a 50 mg daily pill that is not an approved dose.

The diabetes versions give no rate. The Ozempic, Mounjaro and Rybelsus labels list alopecia only among reports received after approval, which they say cannot give a reliable frequency.

The clearest real-world figure is The BMJ study, which followed about 12,000 adults with type 2 diabetes who started a GLP-1 drug. Against people starting SGLT-2 or DPP-4 diabetes drugs, their risk of recorded hair loss was about 1.4 and 1.7 times as high: roughly 7 cases per 1,000 people a year, against 5 and 4.

Most of the rise was in non-scarring hair loss, the group that includes telogen effluvium, though against DPP-4 drugs the study also found a higher risk of scarring hair loss. Cases clustered in the first year, peaking just before month 12. The authors call the absolute risk low. A records study like this shows an association; it cannot prove the drug caused it.

What Nutrient Deficiencies Make GLP-1 Hair Loss Worse?

Low iron, zinc or vitamin D can add to the shedding, and StatPearls notes that hair growth returns once a low level is corrected.

Eating less makes those gaps easier to fall into. In a 2025 study of 69 GLP-1 users in Frontiers in Nutrition, average iron intake was 12.1 mg a day against a reference of 18, and only 43% ate at least 1.2 g of protein per kilogram of adjusted body weight. The study was funded by GNC, the supplement retailer, and written by its staff, so read it for what it measured.

Start with protein. Low protein intake is a listed trigger for this kind of shedding, and smaller meals make a daily target harder to reach. The GLP-1 Protein Calculator works out a target from your weight and activity level.

Zinc is on StatPearls’ list of levels worth correcting, but in the Frontiers study zinc intake was not one of the shortfalls. A supplement makes sense if a test shows you are low, and it is sensible to check with a doctor first.

Biotin is marketed specifically for hair, and deficiency does cause hair loss. But deficiency is rare, and the hair evidence is limited to case reports in children, according to the NIH biotin fact sheet. High doses can also push thyroid and other blood test results falsely high or low, so tell whoever orders your bloodwork if you take it.

Iron is the test to ask for if you are shedding heavily. StatPearls lists a full blood count, serum iron, iron saturation and ferritin, and notes that a normal ferritin does not rule deficiency out. A joint advisory from four US medical and nutrition societies counts excessive hair loss among the signs of a real nutrient deficiency, so raise it with your doctor.

Collagen peptides get added to a lot of routines during weight loss. None of the studies above tested them on hair.

How Do You Reduce the Risk of GLP-1 Hair Loss?

Keep the weight loss from turning into a crash diet, and keep protein and iron covered. The Science Progress review’s prevention list is short: avoid dramatic weight loss and severe calorie cuts, eat enough protein, iron, zinc and vitamin D, and ask whether a slower dose increase suits you.

Prioritise protein in every meal. During the weight-loss phase, a 2025 Delphi consensus on GLP-1 nutrition recommends 1.2 to 1.5 grams of protein per kilogram of actual body weight a day. The guidance is not settled: the four-society advisory reports targets as high as 1.6 proposed during active weight loss, and says it is unclear whether the target should be measured against current weight, adjusted weight or fat-free mass. On a reduced appetite, that means making protein the first thing on the plate. Fish, eggs, Greek yoghurt, cottage cheese, and nuts or seeds are the low-volume sources the advisory names.

Check for iron and ferritin. Ask your GP for the panel above. If iron is low, hair growth returns once it is corrected.

Don’t let variety disappear. Eating the same three low-effort foods every day might feel manageable on a suppressed appetite, but nutrient gaps build up. Use the GLP-1 Meal Plan to build variety into smaller meals without planning it from scratch.

Don’t add a diet on top. A GLP-1 already puts you in a deficit, and crash dieting is on StatPearls’ trigger list.

Supplement the gaps a test finds. Zinc and iron are worth taking when you are low, biotin carries the lab-test warning above, and collagen adds protein.

Which forms and doses have evidence behind them is a separate question from whether to take anything at all. The supplement comparison for GLP-1 users works through the shortlist one product at a time, including what each one is for and who should skip it.

Topical products are a separate lever from nutrition. Shampoos, scalp serums and multi-step kits work on the scalp, and none of them changes the weight loss behind the shedding. Topical minoxidil is FDA-approved only for pattern hair loss, according to StatPearls’ minoxidil chapter, which also lists a burst of shedding among its side effects. The telogen effluvium chapter says it has not been proven to help hair recover there, though some people choose to use it.

If you use minoxidil and have pets, keep them off treated skin and pillows. ASPCA Animal Poison Control warns that even very small exposures can be life-threatening for cats.

If you want something on the scalp while the shedding runs its course, Therapy-G’s 4 Step System Kit is the pick, because it is a four-bottle routine for fine and thinning hair that you can buy without a prescription. If your thinning is a widening part or a receding hairline rather than all-over shedding, ask your doctor about minoxidil instead. Skip the kit if you are hoping it will stop the shedding: nothing on the scalp touches the weight loss behind it, and the steps above come first.

The scalp routine to start with

Therapy-G 4 Step System Kit (90 Day)

Four bottles used in order (a shampoo, a follicle stimulator, a conditioner and a volumizer), sold without a prescription. At $138 for about 90 days, paid once, there is nothing to cancel; the 45-day starter kit is $69 if you want to try the routine first.

The catch: it will not stop GLP-1 shedding, I found no published trial of the kit, and Therapy-G says the follicle stimulator turns the scalp and forehead red for about 25 to 35 minutes. It contains wheat protein.

See the kit at Therapy-G

Affiliate link. If you buy, I may earn a small commission at no extra cost to you.

How I chose: I looked for a scalp product a reader can order today with no prescription and no consultation, and read what is in the box on the seller’s own page. Minoxidil was the other candidate. It is the approved option for pattern hair loss, so it stays with your doctor. I found no published trial of the kit, so treat it as a routine to use while you wait, not a regrowth treatment.

When Does GLP-1 Hair Loss Resolve?

Usually within months. Acute telogen effluvium lasts under six months, and often much less. Regrowth can take up to six months to restart, longer before you notice it, and several months to a year to fill back in fully, according to StatPearls.

The Science Progress review found no strong evidence of permanent damage to follicles. It also notes that few studies report what happens after people stop the drug, so whether stopping speeds recovery is unmeasured. In the GLP-1 communities I read, regrowth while still on the medication is a common report, alongside a smaller group still shedding after a year or more.

You may also read that GLP-1 drugs help hair regrow. The Science Progress review that raises it calls it a hypothesis about hair loss tied to insulin resistance (when the body responds poorly to its own insulin) or polycystic ovary syndrome, resting on a handful of small reports.

If you’re tracking symptoms across your treatment, the GLP-1 Side Effects Tracker logs changes over time so you can see whether the shedding is easing.

Is It Shedding or Pattern Hair Loss?

All-over shedding that starts a few months in points to telogen effluvium. A widening part or a receding hairline points to pattern hair loss, which needs a different plan.

For women in their forties and fifties there is a third possibility. The hormonal shifts of perimenopause can thin hair too, and when that starts around the same time as treatment, the medicine can take the blame. Marilyn Luis covers that side in her guide to perimenopause hair loss, including why HRT is not a treatment for hair loss on its own.

The two behave differently. Telogen effluvium settles on its own. Androgenetic alopecia does not, and it is the one kind of hair loss topical minoxidil is approved for. The Cureus review cites studies proposing that GLP-1 drugs could trigger it in people already prone to it, and its one study that typed the hair loss found it more often than shedding.

The Science Progress review says hair loss should go to a dermatologist if it lasts beyond six to nine months, shows a pattern or rapid thinning of the hairs themselves (what it calls rapid miniaturization), comes with an itchy or inflamed scalp or suggests scarring hair loss, or leaves the cause unclear. If shedding persists, or after fast weight loss or heavy calorie cutting, it says a doctor may consider a blood count, ferritin, a thyroid test and vitamin D to rule out other causes and find deficiencies.

If a doctor confirms pattern thinning and a clinic wait is the obstacle, Musely prescribes hair treatment online: a short medical questionnaire, a reply from one of its doctors within 24 hours, and its minoxidil solution compounded and posted to you from $33 a month on a three-month auto-refill you can pause or cancel. The catch: it is a compounded mix of minoxidil with dutasteride (plus spironolactone in the women’s version), not the approved over-the-counter minoxidil; its doctors can decline to prescribe; the results figures on its site are its own patients’ reports; and it does nothing for the shedding that follows GLP-1 weight loss.

What This Means

GLP-1 hair loss is real and on the labels, at a few people in every hundred in the trials. The best-supported explanation is the weight loss and the eating less that come with it.

Keep protein up, have iron tested if the shedding is heavy, and don’t add a crash diet on top. Give acute shedding six months before judging it. If a test finds low iron, zinc or vitamin D, correcting it lets regrowth start.

Get free GLP-1 tools and guides

The free tools and the guides worth reading first, so you know where to start without digging through the site. No spam, ever.

GLP Playbook - Sitewide Newsletter Capture

This also adds you to my monthly roundup: what is new on the site, plus any discount codes I have that month. The codes only go out in that email.

References

  1. Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls, StatPearls Publishing, last updated 1 May 2024. ncbi.nlm.nih.gov/books/NBK430848
  2. Tang H, et al. Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation. The BMJ, 2026;394:e100077. doi.org/10.1136/bmj-2026-100077
  3. Rojas Lopez RF, et al. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus, 2025;17(8):e90021. doi.org/10.7759/cureus.90021
  4. Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress, 2026;109(2). doi.org/10.1177/00368504261444578
  5. Novo Nordisk. WEGOVY (semaglutide) injection and tablets, prescribing information, DailyMed, June 2026. dailymed.nlm.nih.gov (Wegovy)
  6. Eli Lilly. ZEPBOUND (tirzepatide) injection, prescribing information, DailyMed, revised August 2026. dailymed.nlm.nih.gov (Zepbound)
  7. Novo Nordisk. OZEMPIC (semaglutide) injection, prescribing information, DailyMed, label effective June 2026. dailymed.nlm.nih.gov (Ozempic)
  8. Eli Lilly. MOUNJARO (tirzepatide) injection, prescribing information, DailyMed, label effective August 2026. dailymed.nlm.nih.gov (Mounjaro)
  9. Novo Nordisk. RYBELSUS (semaglutide) tablets, prescribing information, DailyMed, revised January 2026. dailymed.nlm.nih.gov (Rybelsus)
  10. Johnson B, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Frontiers in Nutrition, 2025;12:1566498. Funded by GNC Holdings. doi.org/10.3389/fnut.2025.1566498
  11. Office of Dietary Supplements, National Institutes of Health. Biotin: Fact Sheet for Health Professionals, updated 10 January 2022. ods.od.nih.gov/factsheets/Biotin-HealthProfessional
  12. Mozaffarian D, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine, 2025. doi.org/10.1177/15598276251344827
  13. Sievenpiper JL, et al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: an expert consensus statement using a modified Delphi approach. Obesity Pillars, 2025;17:100228. Funded by Nestlé Health Science. doi.org/10.1016/j.obpill.2025.100228
  14. Patel P, Nessel TA, Kumar D. Minoxidil. StatPearls, StatPearls Publishing, last updated 24 February 2023. ncbi.nlm.nih.gov/books/NBK482378
  15. ASPCA. Minoxidil and Pets: What You Need to Know. 26 February 2026. aspca.org/news/minoxidil-and-pets-what-you-need-know